logo
  

EnPro Industries Reports Q2 Profit; Raises Annual Outlook

EnPro Industries, Inc. (NPO) on Tuesday announced income from continuing operations attributable to EnPro Industries of $29.3 million or $1.41 per share in the second quarter compared with loss of $3.3 million or $0.16 per share in the year-ago quarter.

Excluding items, adjusted income from continuing operations was $32.4 million or $1.56 per share, higher than 18 million or $0.88 per share in the corresponding quarter last year. Analysts polled by Thomson Reuters expected the company to report earnings of $1.24 per share. Analysts' estimates typically exclude special items.

Sales for the quarter increased 20.9% to $298.6 million from $247 million last year, helped by growth in all segments. The consensus estimate was for $273.57 million.

Looking forward to the full year, EnPro is raising its sales outlook to the range of $1.075 billion to $1.125 billion from the previous outlook of $1.05 billion- $1.10 billion. Analysts see sales of $1.09 billion for the period.

The company has also raised its adjusted EPS from continuing operations in the full-year to the range of $5.16 to $5.50 from $4.74 - $5.08 provided earlier. The consensus estimate stands at $4.93 per share.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim's Cyltezo as the first interchangeable biosimilar to AbbVie's top-selling drug Humira or adalimumab. Cyltezo, originally approved in August 2017, is both biosimilar to, and interchangeable with Humira for Cyltezo's approved uses. The Food and Drug Administration may be planning to allow people to receive Covid-19 vaccine booster shot that is different from the initial dose, reports indicate. The agency is likely to make the announcement on mix and match approach on coronavirus booster vaccines on Wednesday. The move will be part of FDA's expected authorization of boosters for the Moderna and Johnson & Johnson vaccines. Drug major Johnson & Johnson on Tuesday raised again its forecast for fiscal 2021 earnings and sales, which are above market view, after reporting higher results in the third quarter. The company's quarterly adjusted earnings also beat market estimates. In pre-market activity on the NYSE, JNJ shares were gaining around 1.24 percent to trade at $162.10.
Follow RTT